<p>Compass Therapeutics（纳斯达克代码：CMPX - 获取免费报告）于周四发布了季度财报。该公司报告季度每股收益为（$0.09），超出市场共识预期的（$0.10）$0.01，FiscalAI 报道。</p>
<p>获取 <strong>Compass Therapeutics</strong> 的提醒：</p>
<h2>Compass Therapeutics 股票上涨 2.5%</h2>
<ul>
<li>分析师仍看好的前三家高动量公司</li>
</ul>
<p>周四，CMPX 股票上涨 $0.14，达到 $5.83。该公司的交易量为 453,195 股，而其平均交易量为 2,287,071 股。该公司的市值为 10.4 亿美元，市盈率为-12.96，贝塔值为 1.48。Compass Therapeutics 的一年最低价为 $1.33，一年最高价为 $6.88。该公司的 50 日移动平均价格为 $5.88，200 日移动平均价格为 $4.77。</p>
<h2>Compass Therapeutics 的机构交易</h2>
<p>一些机构投资者最近调整了对该公司的持股。拉塞尔投资集团在第三季度将其在 Compass Therapeutics 的持股比例提高了 3,933.7%。拉塞尔投资集团目前拥有 7,785 股该公司的股票，价值 27,000 美元，此前在上个季度购买了 7,592 股。Xponance LLC 在第四季度购买了 Compass Therapeutics 的新股份，价值 55,000 美元。CIBC Bancorp USA Inc.在第三季度获得了 Compass Therapeutics 的新职位，价值 37,000 美元。Creative Planning 在第二季度购买了 Compass Therapeutics 的新职位，价值 30,000 美元。最后，胜利资本管理公司在第三季度将其在 Compass Therapeutics 的持股比例提高了 20.6%。胜利资本管理公司目前拥有 12,652 股该公司的股票，价值 44,000 美元，此前在上个季度购买了 2,164 股。目前 68.43% 的股票由机构投资者持有。</p>
<h2>华尔街分析师的看法</h2>
<p>一些研究分析师最近对该公司发表了看法。Weiss Ratings 在 1 月 21 日的研究报告中重新发布了对 Compass Therapeutics 股票的 “卖出（d-）” 评级。威廉·布莱尔在 1 月 5 日的报告中开始覆盖 Compass Therapeutics，并对该公司给予了 “跑赢大盘” 的评级。Canaccord Genuity Group 在 2 月 4 日的研究报告中对 Compass Therapeutics 设定了$13.00 的目标价格。Craig Hallum 在 2 月 13 日的研究报告中开始覆盖 Compass Therapeutics，并设定了 “买入” 评级和$15.00 的目标价格。最后，雷蒙德·詹姆斯金融公司在 1 月 6 日的研究报告中重申了 “跑赢大盘” 的评级，并对 Compass Therapeutics 的股票设定了$9.00 的目标价格。一位投资分析师对该股票给予了强烈买入评级，十二位分析师给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，Compass Therapeutics 目前的共识评级为 “适度买入”，共识目标价格为$13.36。</p>
<p><strong>获取我们关于 Compass Therapeutics 的最新股票报告</strong></p>
<h2>Compass Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Compass Therapeutics, Inc 是一家临床阶段的生物技术公司，致力于新型免疫肿瘤疗法的发现和开发。公司总部位于马萨诸塞州剑桥，专注于工程化单克隆抗体候选药物，旨在增强 T 细胞介导的抗肿瘤反应。Compass 利用专有抗体平台识别和优化调节免疫检查点通路和肿瘤微环境的生物制剂。</p>
<p>该公司的主要项目包括 CTX-471，一种双特异性抗体，靶向 PD-1 和 PD-L1 检查点，以及 DSP107，一种 CD47-SIRPα通路调节剂，旨在破坏癌细胞上的 “别吃我” 信号。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Compass Therapeutics</li>
<li>华尔街害怕的黄金图表……</li>
<li>美国 1776 年再次发生</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>用这四个简单步骤 “防止美联储影响” 你的银行账户</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Compass Therapeutics 吗？</h2>
<p>在你考虑 Compass Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Compass Therapeutics 并不在名单上。</p>
<p>虽然 Compass Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CMPX

<p>Compass Therapeutics（纳斯达克代码：CMPX）报告本季度每股收益为（$0.09），超出预期的（$0.10）$0.01。公告发布后，股价上涨 2.5%，至$5.83。该公司的市值为 10.4 亿美元，市盈率为-12.96。机构投资者持有 68.43% 的股份。分析师的评级意见不一，普遍共识为 “适度买入”，目标价为$13.36。Compass 专注于开发免疫肿瘤疗法，包括针对 PD-1 和 PD-L1 检查点的双特异性抗体</p>

<p>Compass Therapeutics (NASDAQ:CMPX - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01, FiscalAI reports.</p>
<div class="lb-trans"><p>Compass Therapeutics（纳斯达克代码：CMPX - 获取免费报告）于周四发布了季度财报。该公司报告季度每股收益为（$0.09），超出市场共识预期的（$0.10）$0.01，FiscalAI 报道。</p>
</div><p>Get <strong>Compass Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Compass Therapeutics</strong> 的提醒：</p>
</div><h2>Compass Therapeutics Stock Up 2.5%</h2>
<div class="lb-trans"><h2>Compass Therapeutics 股票上涨 2.5%</h2>
</div><ul>
<li>Top 3 High-Momentum Companies Analysts Are Still Bullish On</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师仍看好的前三家高动量公司</li>
</ul>
</div><p>CMPX traded up $0.14 during trading on Thursday, hitting $5.83. The company had a trading volume of 453,195 shares, compared to its average volume of 2,287,071. The company has a market capitalization of $1.04 billion, a PE ratio of -12.96 and a beta of 1.48. Compass Therapeutics has a one year low of $1.33 and a one year high of $6.88. The firm's 50-day moving average price is $5.88 and its 200 day moving average price is $4.77.</p>
<div class="lb-trans"><p>周四，CMPX 股票上涨 $0.14，达到 $5.83。该公司的交易量为 453,195 股，而其平均交易量为 2,287,071 股。该公司的市值为 10.4 亿美元，市盈率为-12.96，贝塔值为 1.48。Compass Therapeutics 的一年最低价为 $1.33，一年最高价为 $6.88。该公司的 50 日移动平均价格为 $5.88，200 日移动平均价格为 $4.77。</p>
</div><h2>Institutional Trading of Compass Therapeutics</h2>
<div class="lb-trans"><h2>Compass Therapeutics 的机构交易</h2>
</div><p>A number of institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. raised its position in Compass Therapeutics by 3,933.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company's stock valued at $27,000 after buying an additional 7,592 shares during the last quarter. Xponance LLC bought a new stake in shares of Compass Therapeutics in the fourth quarter worth $55,000. CIBC Bancorp USA Inc. acquired a new position in Compass Therapeutics during the third quarter worth $37,000. Creative Planning bought a new position in Compass Therapeutics in the second quarter valued at $30,000. Finally, Victory Capital Management Inc. increased its stake in Compass Therapeutics by 20.6% in the 3rd quarter. Victory Capital Management Inc. now owns 12,652 shares of the company's stock valued at $44,000 after buying an additional 2,164 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者最近调整了对该公司的持股。拉塞尔投资集团在第三季度将其在 Compass Therapeutics 的持股比例提高了 3,933.7%。拉塞尔投资集团目前拥有 7,785 股该公司的股票，价值 27,000 美元，此前在上个季度购买了 7,592 股。Xponance LLC 在第四季度购买了 Compass Therapeutics 的新股份，价值 55,000 美元。CIBC Bancorp USA Inc.在第三季度获得了 Compass Therapeutics 的新职位，价值 37,000 美元。Creative Planning 在第二季度购买了 Compass Therapeutics 的新职位，价值 30,000 美元。最后，胜利资本管理公司在第三季度将其在 Compass Therapeutics 的持股比例提高了 20.6%。胜利资本管理公司目前拥有 12,652 股该公司的股票，价值 44,000 美元，此前在上个季度购买了 2,164 股。目前 68.43% 的股票由机构投资者持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><p>A number of research analysts have recently weighed in on the company. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Compass Therapeutics in a research note on Wednesday, January 21st. William Blair started coverage on Compass Therapeutics in a report on Monday, January 5th. They issued an &#34;outperform&#34; rating for the company. Canaccord Genuity Group set a $13.00 target price on Compass Therapeutics in a research note on Wednesday, February 4th. Craig Hallum started coverage on Compass Therapeutics in a research report on Friday, February 13th. They set a &#34;buy&#34; rating and a $15.00 target price for the company. Finally, Raymond James Financial reiterated an &#34;outperform&#34; rating and issued a $9.00 price target on shares of Compass Therapeutics in a research report on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Compass Therapeutics currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $13.36.</p>
<div class="lb-trans"><p>一些研究分析师最近对该公司发表了看法。Weiss Ratings 在 1 月 21 日的研究报告中重新发布了对 Compass Therapeutics 股票的 “卖出（d-）” 评级。威廉·布莱尔在 1 月 5 日的报告中开始覆盖 Compass Therapeutics，并对该公司给予了 “跑赢大盘” 的评级。Canaccord Genuity Group 在 2 月 4 日的研究报告中对 Compass Therapeutics 设定了$13.00 的目标价格。Craig Hallum 在 2 月 13 日的研究报告中开始覆盖 Compass Therapeutics，并设定了 “买入” 评级和$15.00 的目标价格。最后，雷蒙德·詹姆斯金融公司在 1 月 6 日的研究报告中重申了 “跑赢大盘” 的评级，并对 Compass Therapeutics 的股票设定了$9.00 的目标价格。一位投资分析师对该股票给予了强烈买入评级，十二位分析师给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，Compass Therapeutics 目前的共识评级为 “适度买入”，共识目标价格为$13.36。</p>
</div><p><strong>Get Our Latest Stock Report on Compass Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Compass Therapeutics 的最新股票报告</strong></p>
</div><h2>Compass Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Compass Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.</p>
<div class="lb-trans"><p>Compass Therapeutics, Inc 是一家临床阶段的生物技术公司，致力于新型免疫肿瘤疗法的发现和开发。公司总部位于马萨诸塞州剑桥，专注于工程化单克隆抗体候选药物，旨在增强 T 细胞介导的抗肿瘤反应。Compass 利用专有抗体平台识别和优化调节免疫检查点通路和肿瘤微环境的生物制剂。</p>
</div><p>The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.</p>
<div class="lb-trans"><p>该公司的主要项目包括 CTX-471，一种双特异性抗体，靶向 PD-1 和 PD-L1 检查点，以及 DSP107，一种 CD47-SIRPα通路调节剂，旨在破坏癌细胞上的 “别吃我” 信号。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Compass Therapeutics</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>America’s 1776 happening again</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Compass Therapeutics</li>
<li>华尔街害怕的黄金图表……</li>
<li>美国 1776 年再次发生</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>用这四个简单步骤 “防止美联储影响” 你的银行账户</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CMPX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Compass Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Compass Therapeutics 吗？</h2>
</div><p>Before you consider Compass Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Compass Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Compass Therapeutics 并不在名单上。</p>
</div><p>While Compass Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Compass Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Compass Therapeutics（纳斯达克股票代码：CMPX）发布财报，每股收益比预期高出 0.01 美元